Volume 22, Number 11—November 2016
Dispatch
Novel Levofloxacin-Resistant Multidrug-Resistant Streptococcus pneumoniae Serotype 11A Isolates, South Korea
Miey Park, Hyun Soo Kim, Han-Sung Kim, Ji Young Park, Wonkeun Song, Hyoun Chan Cho, and Jae-Seok Kim
Table 2
Antimicrobial susceptibilities of 16 levofloxacin-resistant Streptococcus pneumoniae clinical isolates identified from patients at a hospital in South Korea, 2009–2014*
| Strain |
MIC, μg/mL (resistance) |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LEV |
OFL |
CIP† |
PEN |
AMX |
CRO |
MER |
ERY |
CLI |
VAN |
LZD |
TET |
TIG† |
|
| HM-646 | 16 (R) | 32 (R) | 32 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-669 | 16 (R) | 32 (R) | 32 | >16 (R) | >16 (R) | >16 (R) | 8 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-683 | 8 (R) | 16 (R) | 16 | 4 (I) | 2 (S) | 2 (I) | 1 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-688 | 16 (R) | 32 (R) | 32 | >16 (R) | >16 (R) | >16 (R) | 8 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-730 | 8 (R) | 16 (R) | 8 | 4 (I) | 2 (S) | 2 (I) | 0.5 (I) | >16 (R) | >16 (R) | 0.5 (S) | 0.5 (S) | >16 (R) | 0.03 |
| HM-762 | 32 (R) | 64 (R) | 32 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 0.5 (S) | >16 (R) | 0.015 |
| HM-781 | 16 (R) | 32 (R) | 16 | 16 (R) | 16 (R) | >16 (R) | 8 (R) | >16 (R) | >16 (R) | 0.5 (S) | 0.5 (S) | 16 (R) | 0.03 |
| HM-787 | 16 (R) | 32 (R) | 64 | 16 (R) | 16 (R) | >16 (R) | 8 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-809 | 16 (R) | 32 (R) | 64 | 16 (R) | >16 (R) | >16 (R) | 4 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-854 | 8 (R) | 16 (R) | 16 | 0.06 (S) | 0.06 (S) | 0.5 (S) | <0.015 (S) | 8 (R) | 0.06 (S) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-878 | 16 (R) | 32 (R) | 32 | 16 (R) | >16 (R) | >16 (R) | 8 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | 4 (R) | 0.03 |
| HM-953 | 16 (R) | 32 (R) | 64 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-970 | 32 (R) | 64 (R) | 32 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-1017 | 64 (R) | 128 (R) | 64 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
| HM-1050 | 32 (R) | 64 (R) | 64 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | 0.5 (S) | 0.03 |
| HM-1055 | 16 (R) | 32 (R) | 128 | >16 (R) | >16 (R) | >16 (R) | 16 (R) | >16 (R) | >16 (R) | 0.5 (S) | 1 (S) | >16 (R) | 0.03 |
*AMX, amoxicillin; CIP, ciprofloxacin; CLI, clindamycin; CRO, ceftriaxone; ERY, erythromycin; I, intermediate; LEV, levofloxacin; LZD, linezolid; MER, meropenem; OFL, ofloxacin; PEN, penicillin; R, resistant; S, susceptible; TET, tetracycline; TIG, tigecycline; VAN, vancomycin.
†No susceptibility breakpoints are established for ciprofloxacin and tigecycline.
Page created: October 19, 2016
Page updated: October 19, 2016
Page reviewed: October 19, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.